Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of The Proposed Pegfilgrastim Biosimilar (PF-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers

NCT03273842 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03273842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03273842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of The Proposed Pegfilgrastim Biosimilar (PF-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
October 27, 2017
Completion date
July 25, 2018
Enrollment
422 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers